<?xml version='1.0' encoding='utf-8'?>
<document id="28696229"><sentence text="MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption."><entity charOffset="65-76" id="DDI-PubMed.28696229.s1.e0" text="Rilpivirine" /><entity charOffset="81-89" id="DDI-PubMed.28696229.s1.e1" text="Abacavir" /><pair ddi="false" e1="DDI-PubMed.28696229.s1.e0" e2="DDI-PubMed.28696229.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28696229.s1.e0" e2="DDI-PubMed.28696229.s1.e1" /></sentence><sentence text="Rilpivirine (TMC278) is a highly potent nonnucleoside reverse transcriptase inhibitor (NNRTI) representing an effective component of combination antiretroviral therapy (cART) in the treatment of HIV-positive patients"><entity charOffset="0-11" id="DDI-PubMed.28696229.s2.e0" text="Rilpivirine" /><entity charOffset="13-19" id="DDI-PubMed.28696229.s2.e1" text="TMC278" /><pair ddi="false" e1="DDI-PubMed.28696229.s2.e0" e2="DDI-PubMed.28696229.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28696229.s2.e0" e2="DDI-PubMed.28696229.s2.e1" /></sentence><sentence text=" Many antiretroviral drugs commonly used in cART are substrates of ATP-binding cassette (ABC) and/or solute carrier (SLC) drug transporters and, therefore, are prone to pharmacokinetic drug-drug interactions (DDIs)" /><sentence text=" The aim of our study was to evaluate rilpivirine interactions with abacavir and lamivudine on selected ABC and SLC transporters in vitro and assess its importance for pharmacokinetics in vivo Using accumulation assays in MDCK cells overexpressing selected ABC or SLC drug transporters, we revealed rilpivirine as a potent inhibitor of MDR1 and BCRP, but not MRP2, OCT1, OCT2, or MATE1"><entity charOffset="38-49" id="DDI-PubMed.28696229.s4.e0" text="rilpivirine" /><entity charOffset="68-76" id="DDI-PubMed.28696229.s4.e1" text="abacavir" /><entity charOffset="81-91" id="DDI-PubMed.28696229.s4.e2" text="lamivudine" /><entity charOffset="299-310" id="DDI-PubMed.28696229.s4.e3" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e0" e2="DDI-PubMed.28696229.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e0" e2="DDI-PubMed.28696229.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e0" e2="DDI-PubMed.28696229.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e0" e2="DDI-PubMed.28696229.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e1" e2="DDI-PubMed.28696229.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e1" e2="DDI-PubMed.28696229.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e1" e2="DDI-PubMed.28696229.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e2" e2="DDI-PubMed.28696229.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28696229.s4.e2" e2="DDI-PubMed.28696229.s4.e3" /></sentence><sentence text=" Subsequent transport experiments across monolayers of MDCKII-MDR1, MDCKII-BCRP, and Caco-2 cells demonstrated that rilpivirine inhibits MDR1- and BCRP-mediated efflux of abacavir and increases its transmembrane transport"><entity charOffset="116-127" id="DDI-PubMed.28696229.s5.e0" text="rilpivirine" /><entity charOffset="171-179" id="DDI-PubMed.28696229.s5.e1" text="abacavir" /><pair ddi="false" e1="DDI-PubMed.28696229.s5.e0" e2="DDI-PubMed.28696229.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28696229.s5.e0" e2="DDI-PubMed.28696229.s5.e1" /></sentence><sentence text=" In vivo experiments in male Wistar rats confirmed inhibition of MDR1/BCRP in the small intestine, leading to a significant increase in oral bioavailability of abacavir"><entity charOffset="160-168" id="DDI-PubMed.28696229.s6.e0" text="abacavir" /></sentence><sentence text=" In conclusion, rilpivirine inhibits MDR1 and BCRP transporters and may affect pharmacokinetic behavior of concomitantly administered substrates of these transporters, such as abacavir"><entity charOffset="16-27" id="DDI-PubMed.28696229.s7.e0" text="rilpivirine" /><entity charOffset="176-184" id="DDI-PubMed.28696229.s7.e1" text="abacavir" /><pair ddi="false" e1="DDI-PubMed.28696229.s7.e0" e2="DDI-PubMed.28696229.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28696229.s7.e0" e2="DDI-PubMed.28696229.s7.e1" /></sentence><sentence text="" /></document>